HLA-DRB1 and rheumatoid arthritis: By linking clinical data from the Swedish Rheumatology Register to genetic data from the EIRA study, we evaluated whether known RA susceptibility genes, HLA-DRB1 amino acids, and haplotypes, either individually or integrated into a risk score, predicted treatment response to TNFi therapy.